Gram-Negative Bacterial Infection Therapeutics and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Gram-Negative Bacterial Infection Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gram-Negative Bacterial Infection Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gram-Negative Bacterial Infection Therapeutics Overall Market Size
2.1 Global Gram-Negative Bacterial Infection Therapeutics Market Size: 2021 VS 2028
2.2 Global Gram-Negative Bacterial Infection Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gram-Negative Bacterial Infection Therapeutics Players in Global Market
3.2 Top Global Gram-Negative Bacterial Infection Therapeutics Companies Ranked by Revenue
3.3 Global Gram-Negative Bacterial Infection Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Gram-Negative Bacterial Infection Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Gram-Negative Bacterial Infection Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Gram-Negative Bacterial Infection Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Gram-Negative Bacterial Infection Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Enteral Treatment
4.1.3 Parenteral Treatment
4.1.4 Topical Treatment
4.2 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gram-Negative Bacterial Infection Therapeutics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Gram-Negative Bacterial Infection Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
6.3.2 US Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.3.3 Canada Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.3.4 Mexico Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
6.4.2 Germany Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.3 France Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.4 U.K. Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.5 Italy Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.6 Russia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.4.8 Benelux Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
6.5.2 China Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5.3 Japan Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5.4 South Korea Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.5.6 India Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
6.6.2 Brazil Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.6.3 Argentina Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028
6.7.2 Turkey Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.7.3 Israel Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
6.7.5 UAE Gram-Negative Bacterial Infection Therapeutics Market Size, 2017-2028
7 Players Profiles
7.1 Baxter
7.1.1 Baxter Corporate Summary
7.1.2 Baxter Business Overview
7.1.3 Baxter Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.1.4 Baxter Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.1.5 Baxter Key News
7.2 Sanofi
7.2.1 Sanofi Corporate Summary
7.2.2 Sanofi Business Overview
7.2.3 Sanofi Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.2.4 Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Sanofi Key News
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Corporate Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.3.4 GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.3.5 GlaxoSmithKline Key News
7.4 Novartis
7.4.1 Novartis Corporate Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.4.4 Novartis Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Novartis Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.5.4 Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.5.5 Pfizer Key News
7.6 Takeda
7.6.1 Takeda Corporate Summary
7.6.2 Takeda Business Overview
7.6.3 Takeda Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.6.4 Takeda Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Takeda Key News
7.7 Nektar Therapeutics
7.7.1 Nektar Therapeutics Corporate Summary
7.7.2 Nektar Therapeutics Business Overview
7.7.3 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.7.4 Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Nektar Therapeutics Key News
7.8 Sumitomo
7.8.1 Sumitomo Corporate Summary
7.8.2 Sumitomo Business Overview
7.8.3 Sumitomo Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.8.4 Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Sumitomo Key News
7.9 Targeted Genetics
7.9.1 Targeted Genetics Corporate Summary
7.9.2 Targeted Genetics Business Overview
7.9.3 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Major Product Offerings
7.9.4 Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Targeted Genetics Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Gram-Negative Bacterial Infection Therapeutics Market Opportunities & Trends in Global Market
Table 2. Gram-Negative Bacterial Infection Therapeutics Market Drivers in Global Market
Table 3. Gram-Negative Bacterial Infection Therapeutics Market Restraints in Global Market
Table 4. Key Players of Gram-Negative Bacterial Infection Therapeutics in Global Market
Table 5. Top Gram-Negative Bacterial Infection Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Gram-Negative Bacterial Infection Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Gram-Negative Bacterial Infection Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Gram-Negative Bacterial Infection Therapeutics Product Type
Table 9. List of Global Tier 1 Gram-Negative Bacterial Infection Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gram-Negative Bacterial Infection Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Gram-Negative Bacterial Infection Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Baxter Corporate Summary
Table 31. Baxter Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 32. Baxter Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Sanofi Corporate Summary
Table 34. Sanofi Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 35. Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 38. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 41. Novartis Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 44. Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Takeda Corporate Summary
Table 46. Takeda Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 47. Takeda Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Nektar Therapeutics Corporate Summary
Table 49. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 50. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sumitomo Corporate Summary
Table 52. Sumitomo Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 53. Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Targeted Genetics Corporate Summary
Table 55. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Product Offerings
Table 56. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Gram-Negative Bacterial Infection Therapeutics Segment by Type in 2021
Figure 2. Gram-Negative Bacterial Infection Therapeutics Segment by Application in 2021
Figure 3. Global Gram-Negative Bacterial Infection Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Gram-Negative Bacterial Infection Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Gram-Negative Bacterial Infection Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gram-Negative Bacterial Infection Therapeutics Revenue in 2021
Figure 8. By Type - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Gram-Negative Bacterial Infection Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Gram-Negative Bacterial Infection Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Baxter Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Sanofi Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Takeda Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Nektar Therapeutics Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sumitomo Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Targeted Genetics Gram-Negative Bacterial Infection Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Industry Market Size
